Clinical trials: Glucocorticoids
Colitis, Ulcerative
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients
The purpose of this study is to determine if cobitolimod (former called Kappaproct®) is effective in the treatment of chronic active ulcerative colitis patients not responding to available therapy.
- Trial name
- COLLECT (NCT01493960)
- Testing
- Cobitolimod
- Where
- 37 sites in Czechia, France and 5 more
- Volunteers
- 131 people
- Sponsor
- InDex Pharmaceuticals
Immunoglobulin G4 Related Disease
Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD).
- Trial name
- NCT04520451
- Testing
- rilzabrutinib, Glucocorticoids
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Healthy
CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
This initial Phase I study will evaluate the dose-related safety and tolerability pharmacokinetics (PK) of CORT125281, and CORT125324 (active metabolite), and pharmacodynamics (PD) after single and multiple ascending oral doses…
- Trial name
- NCT03335956
- Testing
- CORT125281, 40mg, fasted, Prednisone 25mg, fasted, Pioglitazone 15mg Tablet
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Prostate Neoplasms
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system…
- Trial name
- NCT00474383
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Cougar Biotechnology, Inc.
Healthy
CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125134 and its active metabolite CORT125201 after single and multiple ascending oral…
- Trial name
- NCT03508635
- Testing
- CORT125134, Mifepristone, Prednisone
- Where
- United Kingdom
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Hypogonadism
A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months
TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.
- Trial name
- NCT06385509
- Testing
- Jatenzo Oral Product
- Where
- 27 sites in United States
- Volunteers
- 116 people
- Sponsor
- Tolmar Inc.
Glucocorticoid-induced Osteoporosis
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.
- Trial name
- NCT06588153
- Testing
- Prolia®
- Where
- 16 sites in China
- Volunteers
- 102 people
- Sponsor
- Amgen
Osteoporosis
Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol
The purpose of this study is to evaluate the efficacy and safety of eldecalcitol monotherapy compared with alfacalcidol monotherapy in patients with glucocorticoid-induced osteoporosis, using a randomized, open-label…
- Trial name
- e-GLORIA (NCT01974167)
- Testing
- Eldecalcitol, Alfacalcidol
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- e-GLORIA trial Protocol Review Committee
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Polymyalgia Rheumatica
A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)
This will be a single-blind, placebo-controlled phase 2 trial to compare prednisolone effects with and without SPI-62 in participants with PMR.
- Trial name
- NCT05436652
- Testing
- SPI-62, Prednisolone 10mg, Additional prednisolone
- Where
- 10 sites in Germany, Poland
- Volunteers
- 66 people
- Sponsor
- Sparrow Pharmaceuticals
Insulin Resistance, Hyperglycemia
Biomarkers of Prednisolone Treatment (P05888)
Primary objective: To identify a biomarker or biomarker-set for the adverse metabolic effects of various doses of prednisolone treatment. Secondary objectives: To describe the PK of prednisolone and PD of a series of biomarkers.
- Conditions
- Insulin Resistance, Hyperglycemia, Glucose Intolerance
- Trial name
- NCT00971724
- Testing
- Prednisolone
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Polymyalgia Rheumatica
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult…
- Trial name
- REPLENISH (NCT05767034)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 132 sites in United States, Argentina and 24 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without…
- Trial name
- SUNFLOWER (NCT07430306)
- Testing
- Anifrolumab
- Where
- 107 sites in United States, Canada and 7 more
- Volunteers
- 245 people
- Sponsor
- AstraZeneca
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to…
- Trial name
- RELIANT (NCT04329949)
- Testing
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 43 people
- Sponsor
- Corcept Therapeutics
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Glucocorticoid-Refractory aGVHD
A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
This is an open-label,single arm,Phase Ib study,in order to evaluate the safety,tolerability, preliminary efficacy and pharmacokinetics of TQ05105 tablets in subjects with Glucocorticoid-Refractory aGVHD
- Trial name
- NCT04941404
- Testing
- TQ05105 tablets
- Where
- 4 sites in China
- Volunteers
- 13 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Allergic Reaction (IgA) Vasculitis
Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis
Hypersensitivity (IgA) vasculitis is a common vascular allergic disease, the cause of which is not yet clear, and may involve infection, immune disorders, heredity and other factors. It belongs to the category of immune diseases.
- Trial name
- NCT07595367
- Testing
- BBD-1 Multi target Immune Enhancement Targeting Agent
- Where
- 2 sites in United States, China
- Volunteers
- 30 people
- Sponsor
- Qifeng Zhang
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or…
- Conditions
- Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03776812
- Testing
- Relacorilant, Nab-paclitaxel
- Where
- 24 sites in United States, Belgium and 3 more
- Volunteers
- 178 people
- Sponsor
- Corcept Therapeutics
Osteoporosis
Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy
To evaluate the effect of subject knowledge of their disease status on persistence in subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment of GIO.
- Trial name
- ACTIVATE (NCT00616694)
- Testing
- Actonel
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Sanofi